Endo International (NASDAQ:ENDP) Updates FY19 Earnings Guidance

Endo International (NASDAQ:ENDP) (TSE:ENL) updated its FY19 earnings guidance on Monday. The company provided earnings per share guidance of $2.00-2.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.17. The company issued revenue guidance of $2.76-2.96 billion, compared to the consensus revenue estimate of $2.86 billion.

Several research firms recently issued reports on ENDP. Royal Bank of Canada lowered shares of Endo International from an outperform rating to a sector perform rating and dropped their price target for the stock from $11.00 to $6.00 in a research report on Thursday, July 11th. BidaskClub lowered shares of Endo International from a sell rating to a strong sell rating in a report on Thursday, July 18th. Morgan Stanley lowered shares of Endo International from an equal weight rating to an underweight rating and dropped their price objective for the stock from $8.00 to $3.00 in a report on Monday, July 15th. Citigroup lowered shares of Endo International from a buy rating to a neutral rating and dropped their price objective for the stock from $19.00 to $5.00 in a report on Monday, June 17th. Finally, Zacks Investment Research lowered shares of Endo International from a buy rating to a hold rating in a report on Wednesday, May 15th. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the stock. Endo International has a consensus rating of Hold and a consensus price target of $10.55.

ENDP stock traded up $0.07 during midday trading on Wednesday, reaching $2.32. The company’s stock had a trading volume of 133,030 shares, compared to its average volume of 5,315,445. The stock’s 50-day moving average price is $3.69. The stock has a market capitalization of $533.79 million, a PE ratio of 0.80 and a beta of 1.14. Endo International has a 52 week low of $2.21 and a 52 week high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $699.71 million for the quarter, compared to analysts’ expectations of $694.60 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The business’s quarterly revenue was down 2.1% compared to the same quarter last year. During the same period last year, the firm posted $0.76 earnings per share. Equities research analysts expect that Endo International will post 2.17 EPS for the current year.

In other news, Director Roger H. Kimmel sold 34,951 shares of Endo International stock in a transaction on Monday, June 17th. The shares were sold at an average price of $3.93, for a total transaction of $137,357.43. Following the transaction, the director now directly owns 148,309 shares of the company’s stock, valued at $582,854.37. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 1.50% of the company’s stock.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Article: Investing in Growth Stocks

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.